Editas Medicine (NASDAQ:EDIT) Rating Reiterated by Royal Bank of Canada
Editas Medicine (NASDAQ:EDIT – Get Free Report)‘s stock had its “sector perform” rating reiterated by equities researchers at Royal Bank of Canada in a report released on Thursday, Benzinga reports. They currently have a $8.00 price target on the stock. Royal Bank of Canada’s target price indicates a potential upside of 112.20% from the company’s […]
21 Sep 02:53 · The Cerbat Gem